Oral Administration of AlequelTM for Patients With Inflammatory Bowel Disease (IBD)

Hadassah Medical Center

Status and phase: Completed; Phase 2; Phase 1

Conditions: Crohn's Disease

Treatments: Drug: Alequel

Study type: Interventional

Funder types: Other

Identifiers

NCT02185183

YI2014-HMO-CTIL

Details and patient eligibility

About

Oral administration of Alequel, a mixture of proteins derived from the patient's bowel will be tested in patients with inflammatory bowel disease.

Full description

Oral administration of Alequel prepared from patients biopsies will be tested in patients with inflammatory bowel disease to determine its anti inflammatory effect.

Enrollment: 22 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Crohn's disease

Exclusion criteria

• Immune suppression

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: Double Blind

---

22 participants in 1 patient group

AlequelTM

Experimental group

Description:

AlequelTM

Treatment:

Drug: Alequel